EXACT Sciences Corp (EXAS)

Troy2008 (99.49) Submitted: 9/14/2009 4:20:06 AM : Start Price: $2.89 EXAS Score: -14.31

I would have started this pitch earlier as I bought thousands of shares at .34 cents but EXAS just became available on Caps with a new 100 million market cap.
With new management in place Exact Sciences will be entering FDA trials with a DNA test that will likely become one of the best all time cancer screening tests to date.
From an investment point of view we will surely see double digits as soon as trials are under way and Wall Street jumps on board.

500% in a year is not out of reach with a relatively small float of 35 million and zero analyst coverage this far.

wymichael (54.19) Submitted: 11/2/2007 7:28:03 PM : Start Price: $4.23 EXAS Score: -14.15

Let's see, would you prefer an invasive test for colon cancer, or a non-invasive one?

theonlypro4U (< 20) Submitted: 9/23/2009 2:56:00 PM : Start Price: $2.89 EXAS Score: -10.11

New management has great credentials from past success, and sell side analysts will pick up coverage in the next few months with strong buys. New health legislation will push prevention, and pay for tens of millions of Americans to get free screening for diseases that can be prevented such as Colon cancer. EXAS will get FDA approval for the best non invasive way to screen for Colon cancer. The shares are under the radar screen now but that will change once analysts publish buy recs. Now is the time for retail investors to purchase for rapid appreciation over the next few months, and for years to come.

chas1232123 (< 20) Submitted: 9/23/2009 10:02:22 AM : Start Price: $2.91 EXAS Score: -11.27

I believe EXAS is greatly undervalued, and will appreciate stongly over the next several years, probably with strong gains from here within a few months. An unexpected reversal of FDA policy a couple of years ago, compounded by terrible general market conditions and management not up to the challenge, combined to drive it way down despite exclusive long term control of very strong technology for a huge, underserved market (colon cancer screening). The negative factors that drove it down have been effectively dealt with, and the primary remaining obstacle is for the market to learn about it. As new management makes more details of their plans public over the next few months, I expect price to appreciate strongly.

SapphireSeas (80.25) Submitted: 10/8/2007 8:23:37 PM : Start Price: $4.69 EXAS Score: -17.43

Exact Sciences' lead product is a DNA-based, non-invasive colorectal screening test, currently being marketed by LabCorp [LH] as PreGen-Plus. Proven much more effective than invasive procedures. The product is likely to be included in revised Multi-Society Task Force guidelines for colorectal screening some time in November 2007. PreGen-Plus is likely to be recommended for screening asymptomatic individuals over age 50 with normal risk factors for colorectal cancer at an interval of every three or five years.

That's a target population of 80 million people - just in the United States.

A good article here from MF contributor Mike Havrilla:

http://seekingalpha.com/article/49188-detecting-big-upside-for-exact-sciences-corporation?source=feed

RationalAnarchy (59.84) Submitted: 10/16/2007 11:01:27 AM : Start Price: $5.88 EXAS Score: -29.85

Solid product with a huge client-base...

Competitive advantage: yes

Uniqueness: (10 best) 7

Small Cap

Room to grow? Yes

kirkydu (99.37) Submitted: 12/20/2007 11:40:01 AM : Start Price: $4.39 EXAS Score: -18.38

Company has large upside gap potential with a new screening test for colon cancer due several important decisions in the next few months.

Buy under 4 with spec money.

tharlow (< 20) Submitted: 10/25/2007 7:39:28 PM : Start Price: $4.30 EXAS Score: -13.45

Ready to explode.

NitroDouglas (< 20) Submitted: 10/9/2007 9:27:06 PM : Start Price: $4.60 EXAS Score: -16.09

With the former CEO of Exact Sciences being hired on by Labcorp, it seems as if there creating a tighter bond between both companies. The product is solid, version 2 of the Pre-Gen Plus looks to be in the 90% detection rate according to a study done by Mount Sinai School of Medicine. With this hard evidence as well as their acceptance of their medicare application in early 2008 could spark good things for Exact.